By Ben Butkus

IQuum, a Boston-area company developing what it calls "lab-in-a-tube" technology for PCR-based molecular testing, said this week that it has been granted emergency use authorization from the US Food and Drug Administration for its influenza A/2009 H1N1 assay.

With the flu season coming to a close in the US and the FDA's EUA period set to expire on June 23, the authorization may not translate into immediate revenue opportunities for IQuum, which is currently scurrying to market the approved test.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.